Drug Profile
Research programme: EphA4 antagonists - UniQuest
Alternative Names: EphA4-Fc; Neurestore - UniQuestLatest Information Update: 13 Sep 2023
Price :
$50
*
At a glance
- Originator University of Queensland
- Developer UniQuest; University of Queensland
- Class
- Mechanism of Action Eph family receptor antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes
Highest Development Phases
- Clinical Phase Unknown Amyotrophic lateral sclerosis; Spinal cord injuries
Most Recent Events
- 31 Dec 2022 Clinical trials in Amyotrophic lateral sclerosis in Australia (Parenteral), prior to December 2022
- 31 Dec 2022 Clinical trials in Spinal cord injuries in Australia (Parenteral), prior to December 2022
- 28 Sep 2020 No recent reports of development identified for preclinical development in Spinal-cord-injuries in Australia (Parenteral)